Marshall Wace LLP Reduces Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Marshall Wace LLP reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 62.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 97,671 shares of the medical equipment provider's stock after selling 159,305 shares during the period. Marshall Wace LLP owned about 0.14% of Lantheus worth $8,738,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Raymond James Financial Inc. purchased a new position in shares of Lantheus during the fourth quarter valued at approximately $36,183,000. Swedbank AB increased its stake in shares of Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after buying an additional 385,000 shares during the period. Keybank National Association OH purchased a new position in shares of Lantheus during the fourth quarter valued at approximately $27,526,000. Norges Bank purchased a new position in shares of Lantheus during the fourth quarter valued at approximately $26,189,000. Finally, Wellington Management Group LLP purchased a new position in shares of Lantheus during the fourth quarter valued at approximately $20,022,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Truist Financial lifted their price target on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. B. Riley dropped their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Finally, JMP Securities restated a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Lantheus has an average rating of "Moderate Buy" and a consensus target price of $129.43.

Lantheus Trading Up 0.9 %

NASDAQ:LNTH traded up $0.93 on Monday, reaching $102.70. 836,798 shares of the stock traded hands, compared to its average volume of 954,694. The company has a market capitalization of $7.03 billion, a price-to-earnings ratio of 17.09 and a beta of 0.20. Lantheus Holdings, Inc. has a 12 month low of $65.76 and a 12 month high of $126.89. The company's fifty day simple moving average is $97.80 and its 200 day simple moving average is $95.08.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.